Cargando…

The Association between Physical Activity and CAMDEX-DS Changes Prior to the Onset of Alzheimer’s Disease in Down Syndrome

Background: People with Down syndrome are at ultra-high risk of developing Alzheimer’s dementia. At present, there are no preventative or curative treatments. Evidence from sporadic Alzheimer’s disease literature suggests that lifestyle factors including physical activity may help maintain cognitive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pape, Sarah E., Baksh, R. Asaad, Startin, Carla, Hamburg, Sarah, Hithersay, Rosalyn, Strydom, Andre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123639/ https://www.ncbi.nlm.nih.gov/pubmed/33925348 http://dx.doi.org/10.3390/jcm10091882

Ejemplares similares

Validating the Cognitive Scale for Down Syndrome (CS-DS) to Detect Longitudinal Cognitive Decline in Adults With Down Syndrome
por: Startin, Carla M., et al.
Publicado: (2019)

Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome
por: Startin, Carla M., et al.
Publicado: (2019)

Differential Associations of Apolipoprotein E ε4 Genotype With Attentional Abilities Across the Life Span of Individuals With Down Syndrome
por: D’Souza, Hana, et al.
Publicado: (2020)

The LonDownS adult cognitive assessment to study cognitive abilities and decline in Down syndrome
por: Startin, Carla M., et al.
Publicado: (2016)

Aging related cognitive changes associated with Alzheimer's disease in Down syndrome
por: Firth, Nicholas C., et al.
Publicado: (2018)

Developing an Informant Questionnaire for Cognitive Abilities in Down Syndrome: The Cognitive Scale for Down Syndrome (CS-DS)
por: Startin, Carla M., et al.
Publicado: (2016)

The validity and reliability of the CAMDEX-DS for assessing dementia in adults with Down syndrome in Brazil
por: Fonseca, Luciana M., et al.
Publicado: (2018)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
por: Startin, Carla M., et al.
Publicado: (2019)

Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years
por: Hithersay, Rosalyn, et al.
Publicado: (2018)

Health comorbidities and cognitive abilities across the lifespan in Down syndrome
por: Startin, Carla M., et al.
Publicado: (2020)

Comparison of Receptive Verbal Abilities Assessed Using the KBIT-2 and BPVS3 in Adults With Down Syndrome
por: Startin, Carla M., et al.
Publicado: (2019)

Comparison of resting-state EEG between adults with Down syndrome and typically developing controls
por: Hamburg, Sarah, et al.
Publicado: (2021)

Dynamic Causal Modeling of the Relationship between Cognition and Theta–alpha Oscillations in Adults with Down Syndrome
por: Hamburg, Sarah, et al.
Publicado: (2019)

Establishing diagnostic thresholds for Alzheimer's disease in adults with Down syndrome: the Cambridge Examination for Mental Disorders of Older People with Down's Syndrome and Others with Intellectual Disabilities (CAMDEX-DS)
por: Beresford-Webb, Jessica A., et al.
Publicado: (2021)

The mismatch negativity as an index of cognitive abilities in adults with Down syndrome
por: Saini, Fedal, et al.
Publicado: (2023)

Susceptibility to COVID-19 Diagnosis in People with Down Syndrome Compared to the General Population: Matched-Cohort Study Using Primary Care Electronic Records in the UK
por: Baksh, R. Asaad, et al.
Publicado: (2022)

Understanding inequalities in COVID-19 outcomes following hospital admission for people with intellectual disability compared to the general population: a matched cohort study in the UK
por: Baksh, R Asaad, et al.
Publicado: (2021)

Diabetes and Obesity in Down Syndrome Across the Lifespan: A Retrospective Cohort Study Using U.K. Electronic Health Records
por: Aslam, Aisha A., et al.
Publicado: (2022)

Assessing general cognitive and adaptive abilities in adults with Down syndrome: a systematic review
por: Hamburg, Sarah, et al.
Publicado: (2019)

Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome
por: Strydom, Andre, et al.
Publicado: (2018)

Structural Connectivity in Down Syndrome and Alzheimer’s Disease
por: Saini, Fedal, et al.
Publicado: (2022)

Identifying individuals with intellectual disability who access mental health support and are at high risk for adverse clinical outcomes: cohort study
por: Baksh, R. Asaad, et al.
Publicado: (2023)

The importance of understanding individual differences in Down syndrome
por: Karmiloff-Smith, Annette, et al.
Publicado: (2016)

Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
por: Montoliu-Gaya, Laia, et al.
Publicado: (2021)

Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease
por: Aschenbrenner, Andrew J., et al.
Publicado: (2021)

The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome
por: Dekker, Alain D., et al.
Publicado: (2018)

Aggressive challenging behavior in adults with intellectual disability: An electronic register-based cohort study of clinical outcome and service use
por: Smith, James, et al.
Publicado: (2022)

Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain
por: Alić, Ivan, et al.
Publicado: (2020)

Correction: Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain
por: Alić, Ivan, et al.
Publicado: (2021)

Predictors of Age of Diagnosis and Survival of Alzheimer’s Disease in Down Syndrome
por: Sinai, Amanda, et al.
Publicado: (2017)

Alzheimer's disease in Down syndrome: An overlooked population for prevention trials
por: Strydom, André, et al.
Publicado: (2018)

Association between Hypothyroidism Onset and Alzheimer Disease Onset in Adults with Down Syndrome
por: Lai, Florence, et al.
Publicado: (2021)

Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium–Down Syndrome (ABC–DS) study
por: Petersen, Melissa E., et al.
Publicado: (2020)

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease
por: Dekker, Alain D., et al.
Publicado: (2017)

The Global Deterioration Scale for Down Syndrome Population (GDS-DS): A Rating Scale to Assess the Progression of Alzheimer’s Disease
por: Rodríguez-Hidalgo, Emili, et al.
Publicado: (2023)

Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study
por: Pentz, Rowan, et al.
Publicado: (2020)

The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer’s Disease
por: Rujeedawa, Tanzil, et al.
Publicado: (2021)

Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome
por: Jones, Emma L., et al.
Publicado: (2013)

The amyloid plaque proteome in early onset Alzheimer’s disease and Down syndrome
por: Drummond, Eleanor, et al.
Publicado: (2022)

Exploring prior diseases associated with incident late-onset Alzheimer’s disease dementia
por: Liao, Jung-Yu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sfcqmp80a5ifci6rpebitd2qdc